Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Top Cited Papers
- 23 August 2013
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 13 (9), 693-701
- https://doi.org/10.1038/nri3516
Abstract
The field of HIV-1 vaccine research has seen a renaissance with the identification of antibodies that neutralize most circulating HIV-1 strains. An understanding of the structural mode of target recognition that these antibodies use and the immune pathways that lead to their development is emerging. This knowledge has provided fundamental insights into the pathways that elicit broadly neutralizing antibodies and provides a foundation for active and passive immunization strategies to prevent HIV-1 infection.Keywords
This publication has 108 references indexed in Scilit:
- Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escapeNature Medicine, 2012
- B-cell–lineage immunogen design in vaccine development with HIV-1 as a case studyNature Biotechnology, 2012
- Antibody-based protection against HIV infection by vectored immunoprophylaxisNature, 2011
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Induction of Immunity to Human Immunodeficiency Virus Type-1 by VaccinationImmunity, 2010
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogensBiochemical and Biophysical Research Communications, 2009
- Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysNature Medicine, 2009
- Structural definition of a conserved neutralization epitope on HIV-1 gp120Nature, 2007